Barriers, Challenges, and Lessons Learned from TiME

Laura M. Dember, M.D.


NIH HCS Research Collaboratory

Steering Committee Meeting

May 23, 2017



TiME Trial Design



Follow-up: median 2.5 years


Barrier	Level of Difficulty				
	1	2	3	4	5
Enrollment and engagement of patients/subjects	X				
Engagement of clinicians and Health Systems			X		
Data collection and merging datasets	X				
Regulatory issues (IRBs and consent)		X			
Stability of control intervention			X		
Implementing/Delivering Intervention Across Healthcare Organizations					X

Patient Enrollment

Lesson:

People are less likely to opt out than to opt in.

Patient Enrollment



Patient and Clinician Engagement

Lesson:

Difficult without either research staff on site OR health system staff who view themselves as part of the research team

- Active, ongoing interaction with clinicians and health system staff is critical – need systems for this
- Staff turnover, changing priorities need to be anticipated

Data Collection and Merging Datasets

Lessons:

- Collaborative approach between IT teams at DCC and health system is important during both trial planning and conduct
- Ongoing data review useful

Regulatory / IRB Issues

Lesson:

There are many experts and many strongly held views -- do not be intimidated; conversations help.

Stability of Control Intervention

Lessons:

- Enthusiasm about the trial question can be a double-edged sword
- Stability of control intervention more likely if trial can be completed quickly

Stability of Control Intervention


- Lots of national attention to dialysis session duration
 - 4-hour treatments almost became a CMS clinical performance measure
 - New clinical practice guidelines include a maximum ultrafiltration rate (usually necessitates a longer session duration)
- We could not have dictated Usual Care session duration and still viewed trial as minimal risk

Implementing / Delivering Intervention Across Health Systems

Lessons:

- Not all interventions are the same
- Important to be able to track delivery of intervention
- Maybe a trial can be too pragmatic

PRECIS Scores



Most Important Lessons

- Progress is incremental
- Not all problems can be solved on the first try
- Celebrate successes, learn from challenges
 - First trial conducted under true partnership between LDOs, academia, NIH
 - -- Largest dialysis trial to date
 - -- Navigated regulatory challenges for waiving consent in high risk patient population, mortality trial
 - -- Use of single IRB for hundreds of sites
 - TiME has generated tremendous interest in moving forward with this approach to evaluate other interventions in dialysis